MSTN and chronic kidney disease: As demonstrated by Wang et al., myostatin level changes in chronic kidney disease could result from the upregulation of inflammatory cytokine, TNFα, through activation of the NF-κB pathway, while myostatin activates the ubiquitin-proteasome and autophagy-lysosome systems via Akt and FoxO3 pathways [183].